Is Fulgent Genetics Stock a Buy? What Investors Should Know
A pandemic darling faces a harsh post-COVID reality.
We rate its business, leadership, balance sheet, and valuation—all in minutes.
• Scoreboard breakdown: business, management, financials, valuation
• From COVID test boom to flat core testing revenue — what changed?
• The Fulgent Pharma acquisition and other management red flags
• Cash burn, negative enterprise value, halted buybacks explained
• Analyst assigns just a 3% “sure thing” probability—here’s why
• Takeaways for biotech investors doing deep due diligence
————————————————————————
This video is brought to you by The Motley Fool.
Visit https://fool.com/Invest to get access to this special offer. The Motley Fool Stock Advisor returns are 1,049% as of 9/2/2025 and measured against the S&P 500 returns of 185% as of 9/2/2025. Past performance is not an indicator of future results. All investing involves a risk of loss. Individual investment results may vary, not all Motley Fool Stock Advisor picks have performed as well.
————————————————————————
